Market Flux Event
Sellas Life Sciences Surges 156% After Cancer Vaccine Cuts Death Risk by 41% in Late-Stage Trial
Read this in the Market Flux appSellas Life Sciences shares surged 156% after the New York-based drugmaker reported positive pivotal Phase 3 data for its experimental cancer vaccine galinpepimut-S in acute myeloid leukemia. The REGAL trial showed the vaccine reduced the risk of death by 41% compared with the best available treatment, with patients receiving it achieving a median overall survival of 24 months versus less than 15 months for those on other therapies.
Capitalizing on the stock move, Sellas simultaneously announced a $150 million public offering of common stock. The company said it intends to grant underwriters an option to purchase additional shares in connection with the offering.
Elsewhere in oncology, Summit Therapeutics launched a new global Phase III trial, HARMONi-10, for its PD-1 x VEGF bispecific antibody ivonescimab in locally advanced, unresectable Stage III non-small cell lung cancer. The study will compare ivonescimab with durvalumab as consolidation therapy in patients who have not progressed following platinum-based concurrent chemoradiation, adding to Summit's already expanding HARMONi clinical program.
The week's activity was framed by the Jefferies Global Healthcare Conference, where dozens of biotechnology and specialty pharma companies including Moderna, Alnylam, Ionis, Allogene, Arrowhead, Arvinas, Denali, Nektar, MannKind, and Nurix presented pipeline and commercial updates. Innate Pharma also reported initial Phase 1 data at the ENA 2026 meeting for IPH4502, its Nectin-4-targeting antibody-drug conjugate with an exatecan payload, from a dose-escalation study enrolling 76 patients with advanced solid tumors.
© AI-generated summary is provided by Market Flux
Sources
- InvestingPolyNovo at Bell Potter Healthcare Conference: margin gains build
- ETMarketsWhile many investors hope that the stocks in their portfolio can deliver multibagger returns of more than 100% in the long term, the shareholders of New York-based Sellas Life Sciences did not have to wait so much as the stock skyrocketed a whopping 156% in just one day after an experimental vaccine for a type of blood cancer helped patients live significantly longer in a late-stage trial. #ETMarkets Read more here
- Business WireInnate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026
- Seeking AlphaPrime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript
- Newsfile_CorpTelo Genomics Announces Term Sheet Providing an Option for Exclusive Worldwide License to AI Technology for Automated Detection of Rare Malignant Cells Full Story: $TDSGF #TELO.CA #TELO.V #Chemicals #Biotechnology #OTC #OTCMarkets #OTCStocks #TSXV
- LiveSquawkPfizer: Enters Exclusive Licensing Agreement With Starna Therapeutics For Autoimmune Diseases - Obtains Exclusive Rights Outside Greater China For Three Pre-IND In Vivo CAR-T Programmes - Starna To Receive Upfront Payment Of $330M - Starna Eligible For Up To $2.30B In Milestone Payments Plus Royalties - Holds Options To Expand Territory To Include Greater China
- NasdaqInnate Pharma S.A. Presents Initial Phase 1 Clinical Data for IPH4502
- Briefingcom$IPHA: Innate Pharma reported Phase 1 data for IPH4502, showing a 33% response rate at the maximum tolerated dose in 6 patients with non-urothelial tumors.
Show 2 more
- BPharmCatalyst$IPHA reported initial Phase 1 IPH4502 data showing manageable toxicity and antitumor activity in solid tumors, including post-EV urothelial cancer. Results showed a 33% ORR at the 3.6 mg/kg MTD in non-urothelial tumors and a 68.4% unconfirmed DCR in urothelial cancer. While encouraging, valuation depends on 2027 dose optimization and establishing durable efficacy in higher-dose post-EV cohorts. $GANX $FTH $ATNM $GTBP $IPHA $XRTX $CUE $AKAN $TCRT $QTRX See More Pre-market Movers at BioPharmCatalyst in the Articles Menu
- OpenOutcrier$IPHA (-17.3% pre) Innate Pharma shares phase 1 data for Nectin-4 ADC IPH4502